Observational research presented in March 2026 at the American Academy of Orthopaedic Surgeons annual meeting found that GLP-1 drugs may slightly increase the risk of developing osteoporosis and gout, a kind of inflammatory arthritis caused by a buildup of uric acid
Purchase five or more vials of the same product to receive 15% off
The real issue is which medically appropriate strategy best supports the patients health profile, goals, risk factors, and long-term sustainability
announced the initiation of a phase 2 clinical trial involving oral VK2735, a dual GLP-1 and GIP receptor agonist
Commercial vendors operating legally will include research-use-only disclaimers on their products and may require purchasers to acknowledge these terms
Efficacy and Safety Endpoints Researchers Track Retatrutide trials track endpoints such as percentage body-weight change, HbA1c, waist circumference, lipids, systolic blood pressure, liver fat, adverse events, serious adverse events, and treatment discontinuation [4], [5], [6], [7], [9]